Lineage Cell Therapeutics, Inc. (LCTX) Net margin 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) net profit margin by fiscal year — reported net income divided by reported revenue.
-436.5%FY2025 · since FY2016: 566.8% → -436.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -436.5% | -240.6 pp |
| FY2024 | -195.9% | +44.3 pp |
| FY2023 | -240.2% | -61.5 pp |
| FY2022 | -178.7% | +812.3 pp |
| FY2021 | -991.0% | +139.8 pp |
| FY2020 | -1130.8% | -797.7 pp |
| FY2019 | -333.1% | +588.9 pp |
| FY2018 | -922.0% | -344.3 pp |
| FY2017 | -577.7% | -1144.5 pp |
| FY2016 | 566.8% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice